PDCD1 and melanoma: In a PopPK analysis of nivolumab administered as adjuvant therapy to patients with melanoma whose tumors were removed by surgical resection, who by definition had neither measurable tumor burden nor further-improved disease state, nivolumab CL was shown to be constant over time, further supporting the correlation between time-varying CL of anti–PD-1 therapies and tumor burden or disease state [16].